Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 10/20 | 0.48 |
| ▸ | FLT1 | P17948 | 9/20 | 0.48 |
| ▸ | PDPK1 | O15530 | 4/20 | 0.47 |
| ▸ | CDK2 | P24941 | 3/20 | 0.47 |
| ▸ | JAK2 | O60674 | 3/20 | 0.47 |
| ▸ | TYK2 | P29597 | 3/20 | 0.47 |
| ▸ | JAK3 | P52333 | 3/20 | 0.47 |
| ▸ | ITK | Q08881 | 2/20 | 0.47 |
| ▸ | AURKA | O14965 | 2/20 | 0.47 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.47 |
| ▸ | ABL1 | P00519 | 2/20 | 0.47 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.47 |
| ▸ | PAK4 | O96013 | 2/20 | 0.47 |
| ▸ | PLK4 | O00444 | 1/20 | 0.47 |
| ▸ | CHUK | O15111 | 1/20 | 0.47 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.47 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.47 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.47 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.47 |
| ▸ | PRKCG | P05129 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4888954 | 0.87 | FGFR1 (0.51) | FGFR1FLT1PDPK1CDK2JAK2 | |
| SCHEMBL4891227 | 0.86 | ITK (0.45) | FGFR1FLT1PDPK1CDK2JAK2 | |
| SCHEMBL4891748 | 0.86 | PAK4 (0.43) | FGFR1FLT1PDPK1CDK2PAK4 | |
| SCHEMBL5287383 | 0.85 | ITK (0.43) | FGFR1FLT1PDPK1CDK2JAK2 | |
| SCHEMBL4914751 | 0.84 | AURKA (0.59) | FGFR1FLT1PDPK1CDK2JAK2 | |
| SCHEMBL5189724 | 0.84 | AURKA (0.43) | FGFR1FLT1PDPK1CDK2AURKA | |
| SCHEMBL5189400 | 0.83 | ITK (0.45) | FGFR1FLT1PDPK1CDK2JAK2 | |
| SCHEMBL4894195 | 0.83 | AURKA (0.50) | FGFR1FLT1PDPK1CDK2JAK2 | |
| SCHEMBL5954843 | 0.82 | AURKA (0.44) | FGFR1FLT1PDPK1CDK2JAK2 | |
| SCHEMBL5954198 | 0.82 | AURKA (0.47) | FGFR1FLT1PDPK1CDK2JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2008524151-A | — | — | 2008-07-10 | — | — | JP | claimed |
| EP-1644335-A4 | TETRAHYDROQUINOLINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2008-06-04 | — | — | EP | claimed |
| EP-1831224-A2 | TRYCYCLIC HETEROCYCLES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. Hoffmann-Roche AG (CH) | 2007-09-12 | — | — | EP | claimed |
| US-20060142247-A1 | Tricyclic heterocycles | HOFFMANN-LA ROCHE INC. | 2006-06-29 | — | — | US | claimed |
| WO-2006063841-A2 | TRYCYCLIC HETEROCYCLES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-22 | — | — | WO | claimed |
| EP-1644335-A1 | TETRAHYDROQUINOLINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS | Bristol-Myers Squibb Company (US) | 2006-04-12 | — | — | EP | claimed |
| WO-2005007628-A1 | TETRAHYDROQUINOLINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-01-27 | — | — | WO | claimed |
| EP-1831224-A2 | TRYCYCLIC HETEROCYCLES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. Hoffmann-Roche AG (CH) | 2007-09-12 | — | — | EP | disclosed |
| US-20060142247-A1 | Tricyclic heterocycles | HOFFMANN-LA ROCHE INC. | 2006-06-29 | — | — | US | disclosed |
| WO-2006063841-A2 | TRYCYCLIC HETEROCYCLES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142247-A1 | Tricyclic heterocycles | CYP11B1, CYP11B2, CYP3A43 | FGFR1 2228/4885FLT1 4208/4885PDPK1 2511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.